Kidney doctor's shooting comes as questions emerge about dialysis centers
Dr. Andre Obua drove 18 hours from Miami to Terre Haute, Indiana. He pulled up to the home of a local kidney specialist and allegedly opened fire, striking the kidney doctor in the hand before being wrestled to the ground.
The only thing more unexpected than the act of violence was the apparent motive.
Accused in the shooting, which occurred one month after the brazen murder of the UnitedHealthcare CEO in New York City, was Obua, a highly educated medical resident with a promising career. But Obua had become fixated on one of the least-understood corners in the big business of medicine — kidney dialysis.
In letters penned from prison, in phone interviews and on a website he created, Obua shared with CBS News his grievances, discussed the Luigi Mangione case in New York, and offered hints to the underpinnings of an alleged act that landed him in jail, where he is awaiting trial on attempted murder charges. He would not directly discuss the shooting and has pleaded not guilty.
Prosecutors in Vigo County, Indiana, said they consider the crime abhorrent — and a source of continued pain for the physician who was shot. CBS News is not naming the victim at the request of prosecutors. Prosecutor Terry R. Modesitt said his office determined the victim "had never done anything to justify having violence brought against him." Modesitt voiced a broader concern about what he said he fears is a growing wave of disturbing vigilante violence that has no place in a civilized society.
"These cases that we read about in the news or watch on TV about the news — there's no excuse for this," Modesitt said. "Go out and protest. Write your congressman… file a complaint with the attorney general's office in your state, things like that. But no, there's never any justification to go try to murder someone."
Tom Mueller, the author of "How to Make a Killing: Blood, Death and Dollars in American Medicine," spent more than five years studying the dialysis industry. He says the incident conjures many of the same complex swirl of emotions that Americans expressed after the UnitedHealthcare shooting. There is a visceral disgust for violence used to make a statement, he said. And there is long-running dismay about the shortcomings of America's health care system, which may be costing lives. That includes, he said, a rise of for-profit dialysis clinics and their impact on quality of care for those confronting end-stage kidney disease.
"Unless we can talk about systemic harm done by the medical profession, the insurance profession, against patients … we're not gonna get anywhere," Mueller said.
Mueller may be uniquely positioned to weigh in on both the crime and the issue that may have been underlying it. For months before the shooting, he told CBS News that he and Obua had been corresponding by email about his book. In those emails, which he described to CBS News, he says Obua never gave any indication he was spiraling towards violence. Mueller only learned of the shooting later, during an interview with CBS News.
"I nearly fell off my chair when I heard," Mueller said. "My sense is that [his] level of desperation just must have found an outlet in a violent act."
Dialysis under scrutiny
LaQuayia "LQ" Goldring, 28, has been a dialysis patient for the past ten years. Goldring lives near Louisville, Kentucky, where she spends up to four and a half hours a day hooked up to a home dialysis machine. It acts as her kidneys, taking the blood from her body, removing the waste, then cycling it back in.
"Every day I wake up, I'm thanking God that my feet even hit the ground and that my eyes open and I can still breathe on my own," she said.
Goldring is one of roughly 500,000 Americans dependent on dialysis to stay alive as they wait and hope for a kidney transplant, the only available remedy for those suffering from end-stage kidney disease. She receives the treatment at home, and says dialysis clinics left her with no control over her care, treating her like a "check." She, like Mueller, believes the industry has become too focused on profits.
"This is emergency room care done in the mall," Mueller said. "People are not given the tailored treatment that they need."
A review of federal data by CBS News found one-third of dialysis clinics failed to meet federal standards this year — nearly 2,500 of the roughly 7,600 clinics nationwide. The average score was 60 out of 100 possible points.
Criticism of the industry has been disputed by the two largest for-profit companies in the dialysis industry, Fresenius and DaVita.
Fresenius told CBS News in a statement that the company maintains an "unwavering focus on improving quality of life, strengthening clinical outcomes, and extending the lifespan of those we have the privilege to serve." DaVita said in a statement that its "dedicated clinicians consistently deliver high-quality, individualized care in a complex clinical and regulatory environment."
A health care "duopoly"
The two companies dominate the national landscape of clinics where kidney patients come to receive regular dialysis treatments — crucial to keeping them alive. Roughly 90% of patients get their treatment in the outpatient clinics. And together, the two for-profit companies own nearly 75% of all U.S. clinics — nearly 5,600 in total.
The companies have become what Mueller calls "a duopoly" as the industry has consolidated over the past three decades. The share of independently owned dialysis facilities fell from 86% to 21% during that period. In over 2,500 cities around the U.S., a single company owns every clinic.
That industry dominance has a cost, according to Ryan McDevitt, a Duke University economist who co-authored a study released this month looking at the toll of the scarce competition.
"This is the most concentrated health care sector across the entire U.S.," McDevitt said.
McDevitt argues that Medicare's limits on how much it reimburses clinics per patient have incentivized DaVita and Fresenius to focus on filling chairs to increase their profit margins. Both companies reject that characterization.
Last year alone, DaVita delivered more than 29 million dialysis treatments, earning $391 in revenue per session. That includes providing home dialysis treatments, like Goldring receives through Fresenius. Together, Davita and Fresenius reported a total of $33.7 billion in revenue from all of their businesses.
McDevitt said his research found that when independent clinics are acquired by DaVita or Fresenius, their transplant referrals drop by about 10%, their patient survival rates fall by 2%, hospitalizations increase by 5%, and infection rates go up by about 12%.
While kidney specialists typically dictate the type of care they want for their patients, some doctors told CBS News they felt pressure from the companies running the dialysis clinics to move patients through faster. Dr. Leonard Stern, a nephrologist now at Columbia University, said even if he believed a patient needed five hours of dialysis treatment, there were times that DaVita would refuse.
"We have a corporate model that provides the least amount of care for the most amount of profit for shareholders," Stern said.
Stern served as medical director of an independent for-profit dialysis center until 2005, when it was sold to DaVita. After the acquisition, he said there were times the company instructed him to make more room for new patients. He said that sometimes meant more billing for DaVita, even if it resulted in unnecessary complications and return visits for his patients.
Stern left the clinic in 2013.
Dr. Jeffrey Gold, a kidney specialist in Royal Oak, Michigan, said the doctors feel pressure to "get the next patient in — and make sure everybody has a spot to dialyze."
McDevitt described the one-size-fits-all approach as inconsistent with patient needs.
"They call it bazooka dialysis, where they pump you through the station as quickly as possible," McDevitt said, comparing the turnover model to any other volume business. "They need to turn over stations multiple times a day to hit those profit numbers, to keep shareholders happy."
Reports of deficiencies
Most dialysis patients rely on the federal government to pay for the treatment. The costs add up to about $40 billion a year, according to the American Association of Kidney Patients.
"It's actually one percent of the entire federal budget, which is a staggering statistic," McDevitt said.
Despite the expenditures — about $100,000 per patient, according to McDevitt — the U.S. has among the highest death rates for patients on dialysis among developed nations.
For years, health surveyors from the Center for Medicare and Medicaid Services (CMS) have conducted routine monitoring of dialysis clinics to assess their performance.
Since 2013, those officials have cited U.S. dialysis centers for more than 115,000 deficiencies, including poor hand hygiene, unsanitary conditions while handling IV medications, and inadequate training.
CMS assigns every facility a "Total Performance Score," evaluating them annually on measures like patient safety, infection control and hospitalization rates. If the score is below CMS standards, the clinic is hit with a financial penalty.
A CBS News review of federal data found more than 40% of the clinics run by the nation's two largest dialysis providers — DaVita and Fresenius — failed to meet those same standards this year. That's nearly 1,600 clinics.
In separate statements to CBS News, both companies highlighted their performance, saying the data reflects a track record of "exemplary care."
Fresenius noted that more than 65% of its dialysis centers received three stars or higher on Medicare's five-star scale — a rate the company said is higher than the national average of all U.S. dialysis providers. The company also said its employees "take immense pride in providing best-in-class, high-quality care to our patients."
DaVita said in a statement to CBS News that problems in clinics were "rare and isolated" and represent "exceptions and do not reflect the exemplary care we consistently provide."
"We take every concern seriously, and if we make an error, we work immediately to resolve it," DaVita said in its statement. "To mischaracterize such anomalies as systemic care failures is reckless, fear-mongering, and puts patient well-being at risk."
Legal settlements top $1 billion
The dialysis industry has faced legal scrutiny over the past decade from patients, their surviving relatives, and from state and federal agencies.
One ongoing federal case against Fresenius accuses the firm of trying to fraudulently obtain hundreds of millions of dollars of federal funds by performing unnecessary procedures — an allegation the company denies. The two companies have settled at least 25 lawsuits. And CBS News has found that since 2015, Fresenius and DaVita paid out at least $1.13 billion in legal settlements.
"I have not seen any improvement in care following these settlements," McDevitt said.
A spiral towards violence
Frustration over the lack of reform in the industry has been simmering for years, Mueller told CBS News. Which is why Mueller said he was not unnerved as he exchanged emails with a Miami-based medical resident who had taken an interest in dialysis — and specifically, the use of a specific medication he thought could be harming patients.
"The kinds of emails he sent were totally rational, very thoughtful, extremely data-driven," Mueller said, calling Andre Obua "the last person in the world I would think to commit a violent act."
Over dozens of pages, the letters Obua sent to CBS News from jail describe how he grew up in a low-income household in Ann Arbor, Michigan — a background that "shaped my world views and motivates me to advocate for the less fortunate," he wrote.
He says he first heard during an internal medical rotation about the use of a medication being prescribed to kidney patients to speed up the dialysis process, which he speculated could be endangering their health. It appears from his writing that this concern went from being an interest to being an obsession.
At one point, he described seeking out a lawyer to file a whistleblower lawsuit, but was ultimately persuaded he could not succeed in court.
CBS News sought to verify his claims, but no kidney expert interviewed believed that the medication in question harmed patients. Nevertheless, Obua unspooled mountains of his research, theories and accusations on a public website.
A source familiar with the case told CBS News Obua had drawn up a list of kidney doctors to target. Near the top was the victim of his attack in Indiana.
In January, for reasons Obua would not directly address in his letters and conversations with CBS News, the 29-year-old said he loaded his car with firearms and a bag of Monopoly money — which he noted was similar to the one left behind by alleged UnitedHealthcare shooter Luigi Mangione — and headed north towards Indiana.
Police reports say Obua fired at a Terre Haute kidney specialist without warning, striking the doctor in the hand. The two wrestled in the tranquil suburban driveway until police arrived and placed Obua under arrest.
Mueller shakes his head when thinking about the bright future Obua seemingly abandoned that winter evening.
"It says we're living in extreme times," he said. "And it's a tragic, tragic event."
Modesitt, the prosecutor, said he has no sympathy for the young medical resident who's now facing attempted murder charges.
"If you've got a problem in any way with the system or anything else, we have attorney generals, we have secretary of states, different entities that you can file a complaint with," Modesitt said. "But it's never justified to take the law in your own hands."
Obua is scheduled to go on trial in August.
Full statement of DaVita:
Our dedicated clinicians consistently deliver high-quality, individualized care in a complex clinical and regulatory environment. We understand that in any healthcare setting, rare and isolated incidents may occur. However, these are diligently addressed as exceptions and do not reflect the exemplary care we consistently provide. We take every concern seriously, and if we make an error, we work immediately to resolve it. To mischaracterize such anomalies as systemic care failures is reckless, fear-mongering, and puts patient well-being at risk.
Full statement of Fresenius Medical Care:
Providing high-quality care is our standard, and nothing gets in the way of our patients being our North Star. By any objective measure, our ability to hire qualified staff, deliver outstanding – best-in-class – patient care, and innovate for the betterment of people living with kidney disease far outpaces the industry. This is evidenced by the fact that the most recently available CMS (Centers for Medicare & Medicaid Services) 5-Star quality data, which concluded that more than 65% of all Fresenius Kidney Care (FKC) dialysis centers received 3 stars or higher – higher than the combined national average of all U.S. dialysis providers. Our approximately 70,000 employees and care teams, working across more than 2,600 dialysis centers, and delivering over 31 million treatments annually in the U.S. take immense pride in providing best-in-class, high-quality care to our patients. And our ability to introduce revolutionary advancements and innovation in kidney care, including the upcoming introduction of the 5008X™ CAREsystem in the U.S. that will deliver high-volume hemodiafiltration starting later in 2025, demonstrates our unwavering focus on improving quality of life, strengthening clinical outcomes, and extending the lifespan of those we have the privilege to serve.
Netanyahu reacts to U.S. strikes on Iranian nuclear sites
Some key Democratic congressional leaders left out of Trump's Iran attack plans
Extended interview: LQ Goldring on her quest for a kidney donor
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Mahmoud Khalil speaks to ABC News in 1st broadcast interview after ICE release
Watch more of Linsey Davis' broadcast interview with Mahmoud Khalil on "Good Morning America" Monday at 7 a.m. ET and ABC News Live Prime at 7 p.m. ET. Mahmoud Khalil, the Columbia University pro-Palestinian activist who was detained by ICE for more than three months, spoke with ABC News Live Prime anchor Linsey Davis in the first on-camera interview since his release. In the interview, which is set to air on Monday at 7 p.m. ET, Khalil pushed back against the Trump administration's claim that he is a threat to U.S. national security. "The White House has said that you distributed pro-Hamas fliers. Secretary Rubio said that you created an environment of harassment toward Jewish students. President Trump said we got to get him the hell out of our country. Why do you think that you are perceived as such a threat?" Davis asked Khalil in the exclusive interview. "Because I represent a movement that goes against what this administration is trying to do," Khalil responded. "They try to portray me as a violent person. They try to portray me as a terrorist, as some lunatic, but not presenting any evidence, not presenting any shred of credibility to their claims." Khalil was released Friday evening from an Immigration and Customs Enforcement (ICE) facility in Jena, Louisiana, after U.S. District Judge Michael Farbiarz issued an order granting his release on bail. The judge said the government made no attempt to prove that Khalil's release would irreparably harm them in some way and that Khalil represented a flight risk. "What all that evidence adds up to is a lack of violence, a lack of property destruction, a lack of anything that might be characterized as incitement to violence," Farbiarz said of Khalil. The judge said that the conditions of Khalil's release shall not include electronic monitoring or a requirement that a bond be immediately posted. "The hundreds of men who are left behind me shouldn't be there in the first place," Khalil told reporters on Friday, referring to others being detained. "The Trump administration are doing their best to dehumanize everyone here. Whether you are a U.S. citizen, an immigrant or just a person on this land, doesn't mean that you are less of a human." MORE: Mahmoud Khalil released from ICE custody in Louisiana The ruling to release Khalil came at the same time an immigration judge in Jena, Louisiana, denied Khalil's request for asylum and ordered him to remain detained. Farbiarz's order superseded that ruling. The Department of Homeland Security sharply criticized the judge's decision to release Khalil, claiming in a statement on Friday that the ruling is "yet another example of how out-of-control members of the judicial branch are undermining national security," and arguing "an immigration judge, not a district judge, has the authority to decide if Mr. Khalil should be released or detained." "Their conduct not only denies the result of the 2024 election, it also does great harm to our constitutional system by undermining public confidence in the courts," the statement continued. Khalil, a green card holder who is married to an American citizen, was a graduate student at Columbia University's School of International and Public Affairs (SIPA) during a series of pro-Palestinian protests on campus against the Israeli military campaign in Gaza. MORE: Judge rules Trump administration cannot continue to detain Palestinian activist Mahmoud Khalil Khalil was detained in March, with the Trump administration saying then in part that his continued presence in the country would pose a risk to U.S. foreign policy. However, Judge Farbiarz issued a preliminary injunction last week barring the Trump administration from continuing to detain him based on that assertion. Khalil was detained for an additional week until his release on Friday after the government argued for his continued detention based on their allegation that he misrepresented information on his green card application, an allegation that Khalil and his attorneys deny. Khalil, a grandson of Palestinian refugees who was born in Syria and has Algerian citizenship, welcomed his first child, a son named Deen, while he was in custody. Khalil thanked his supporters during a press conference in New York on Saturday and vowed to continue to speak out for Palestinian human rights. "Even if they would kill me, I would still speak up for Palestine," Khalil said.
Yahoo
an hour ago
- Yahoo
New Data Show Delve Bio's Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing
Data Presented at the 2025 American Society for Microbiology Microbe Conference BOSTON, June 22, 2025--(BUSINESS WIRE)--Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at the American Society for Microbiology (ASM) Microbe conference in Los Angeles showing the impact of metagenomic sequencing for transforming infectious disease diagnostics by offering advances compared to traditional microbiological testing. Among the data presented at the meeting is a comparison of Delve's metagenomic cerebrospinal fluid (CSF) test, Delve Detect CSF, compared to a traditional PCR-based meningitis/encephalitis (ME) panel. The study reanalyzed samples from a diverse patient cohort previously tested using the ME panel. The data showed that mNGS can be used in conjunction with microbiological testing to increase diagnostic yield by identifying pathogens that are not detectable with traditional, pathogen-specific panel testing. The inclusion of mNGS tests like Delve Detect, which has a 48-hour turnaround time, can shorten time to diagnosis, enabling clinicians to initiate targeted therapies sooner. "This study showed substantial agreement between Delve Detect and a syndromic PCR panel. But importantly, Delve Detect also identified pathogens that were not included on the PCR panel and would have been missed as causes of a patient's infection if mNGS were not included in the diagnostic workup," said Benjamin Bradley, M.D., Ph.D., medical director of virology and molecular infectious diseases at ARUP Laboratories. "This study supports including mNGS in the diagnostic workup for patients with complex central nervous system infections." The study included 122 samples — 47 positive and 75 negative. Analysis showed that in comparison with the ME panel, Delve Detect CSF demonstrated approximately 10% higher positivity rate (48% vs. 38%), with an additive diagnostic yield of 24%. This added yield included detection of multiple co-infections, 16 unique organisms not included in the ME panel, and positive detections in 19 samples (25%) that were negative by the ME panel. Additionally, in samples that were negative by both tests, Delve Detect CSF showed high agreement (95%) with the ME panel, supporting the negative predictive value of mNGS. The company's full presence at ASM Microbe 2025 includes: Delve's chief medical officer Steve Miller, M.D., Ph.D. hosted A New Era: Metagenomic Sequencing for Comprehensive Pathogen Detection, exploring real world evidence, clinical cases and considerations for laboratory teams implementing mNGS. Presentation of a case report in a feature poster, Using Metagenomic Sequencing to Diagnose a Novel Moraxella CNS Shunt Infection in a Culture-Negative Case Presentation of data comparing the company's mNGS CSF test, Delve Detect, to a widely used, PCR meningitis/encephalitis panel as part of the session Assessing the Clinical Impact of Next-Generation Sequencing: Where Are We Now? "These presentations at ASM highlight the transformation underway in infectious disease diagnostics. Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not deliver a diagnosis and speed is critical," said Brad Murray, chief executive officer of Delve Bio. "We're working to make this technology more widely available to neurologists, infectious disease physicians and laboratory teams so they can get patients the answers they need." Conference attendees are also invited to visit Delve Bio at booth #1440 to learn more about the company's metagenomic platform, including Delve Detect and its proprietary bioinformatics platform Delve Decide. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit View source version on Contacts Company Contact Amy WongSenior Director of Marketing and Business Development, Delve BioEmail: media@ Media Contact Julie McKeough42 North for Delve BioEmail: julie@ Sign in to access your portfolio
Fox News
an hour ago
- Fox News
Over 700 Iranian nationals released into US during Biden administration despite terrorism concerns
Over 1,500 Iranian nationals who illegally entered the U.S. at the southern border were arrested during the Biden administration, and nearly 50% of them were released back into the country, according to a senior U.S. Customs and Border Protection (CBP) source. More specifically, Border Patrol agents arrested 1,504 Iranian nationals from fiscal year 2021 through fiscal year 2024. Of the 1,504 individuals who were arrested, 729 were released into the U.S. The number of Iranian nationals arrested at the southern border increased year-to-year, with 48 being arrested in FY21; 197 in FY22; 462 in FY23 and 797 in FY24. Likewise, the number of Iranian nationals released also increased, with 12 in FY21; 40 in FY22; 229 in FY23; and 448 in FY24. It is unclear how many of the Iranians released into the U.S. were on the terrorism watchlist, as the Biden administration repeatedly denied Fox News' Freedom of Information Act requests and appeals for the data. The Biden administration cited "privacy concerns" of the people on the list, as well as "minimal public interest" for denying the requests. Still, there were over 2 million known gotaways at the border during the Biden administration, and because they were never caught, there is no way of knowing where the individuals were from. All Iranians are considered "special interest aliens" because of national security concerns. Therefore, they are supposed to receive enhanced vetting from the Department of Homeland Security (DHS). The news comes as U.S. officials sound the alarm regarding the threat of terror-backed sleeper cells in the country just hours after President Donald Trump ordered the successful strikes on key nuclear facilities within Iran. Hours after Trump addressed the nation about the military strikes, the DHS issued a memo sounding the alarm to a "heightened threat environment" in the U.S. While the bulletin did not cite any specific threats, it came as Iranian officials vowed retaliation against the U.S. The bulletin points to law enforcement within the U.S. disrupting "multiple potentially lethal Iranian-backed plots" since 2020, while noting the Iranian government's unsuccessful attempts to target critics of its regime. The advisory comes after Trump ordered military strikes on Iran's key nuclear facilities in what officials are calling "Operation Midnight Hammer," prompting law enforcement to be on high alert regarding the threat of foreign adversary operatives conducting an attack on U.S. soil, with thousands of Iranian nationals previously crossing over the border. "Because of the open borders, we are at a serious catch-up phase," Former FBI assistant director Chris Swecker told Fox News Digital. "We don't know where those thousand Iranians are and who knows how many others got across the border. We missed an opportunity when they caught and released those thousand. We missed the opportunity to gather intel by interviewing them and thoroughly vetting them. We just simply let them go, which is gross negligence on the part of the Biden administration." The possibility of foreign cells carrying out a domestic terror plot was pushed into the national spotlight last year after federal prosecutors announced a member of Iran's Islamic Revolutionary Guard Corps and two U.S.-nationals were arrested for allegedly plotting to murder then-President-elect Trump and a U.S. citizen critical of the Iranian regime.
